Inovio Pharmaceuticals stock rises 8.77% and outperforms competitors
Updated
Updated · MarketWatch · May 6
Inovio Pharmaceuticals stock rises 8.77% and outperforms competitors
11 articles · Updated · MarketWatch · May 6
Shares closed at $1.24 on Wednesday as trading volume reached 3.0 million, above the 50-day average of 1.8 million.
The gain came in a broader market rally, with the Nasdaq Composite up 2.02% and the Dow Jones Industrial Average rising 1.24%.
Inovio still finished 58.37% below its 52-week high of $2.98 reached on 9 September, while Johnson & Johnson fell, Statera was flat and Pfizer edged higher.
With cash reserves dwindling, can Inovio's lead drug overcome a key FDA hurdle before its October deadline?
Can a new cancer therapy trial save Inovio if its lead drug falters under FDA scrutiny?